Dianthus Therapeutics, Inc. $DNTH is Catalio Capital Management LP’s 5th Largest Position

Catalio Capital Management LP lessened its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 2.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 653,572 shares of the company’s stock after selling 14,043 shares during the period. Dianthus Therapeutics accounts for approximately 5.0% of Catalio Capital Management LP’s holdings, making the stock its 5th biggest position. Catalio Capital Management LP owned about 1.51% of Dianthus Therapeutics worth $26,934,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of DNTH. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after buying an additional 618 shares in the last quarter. American Century Companies Inc. grew its position in shares of Dianthus Therapeutics by 13.2% during the second quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock valued at $1,009,000 after purchasing an additional 6,323 shares in the last quarter. Invesco Ltd. grew its position in shares of Dianthus Therapeutics by 31.1% during the second quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock valued at $390,000 after purchasing an additional 4,962 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of Dianthus Therapeutics by 14.5% during the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock valued at $21,887,000 after purchasing an additional 149,200 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Dianthus Therapeutics during the second quarter valued at about $27,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Trading Up 3.8%

Shares of NASDAQ:DNTH opened at $81.89 on Thursday. Dianthus Therapeutics, Inc. has a 12 month low of $16.64 and a 12 month high of $96.50. The company has a 50-day moving average price of $86.81 and a 200 day moving average price of $66.00. The company has a market cap of $4.48 billion, a price-to-earnings ratio of -19.83 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The firm had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. As a group, equities analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Insider Transactions at Dianthus Therapeutics

In related news, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the completion of the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $362,480. This trade represents a 86.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Ryan Savitz sold 114,367 shares of the stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total transaction of $9,492,461.00. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 149,121 shares of company stock valued at $12,635,454. 3.02% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on DNTH. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Truist Financial raised their price objective on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 9th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Stifel Nicolaus set a $120.00 price objective on Dianthus Therapeutics in a research report on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $117.82.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.